Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates

Advanced Drug Delivery Reviews

Volumn 53, Issue 3, 2001, Pages 247-264

  Senter, Peter D ^a   Springer, Caroline J ^b  

^a SEATTLE GENETICS INC   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cancer; Enzymes; Monoclonal antibodies; Prodrugs; Targeting

Indexed keywords

ANTIGENS; DRUG THERAPY; ENZYMES; MONOCLONAL ANTIBODIES; TUMORS;

RADIONUCLIDE CONJUGATES;

DRUG PRODUCTS;

ALKALINE PHOSPHATASE; ALPHA GALACTOSIDASE; AMINOPEPTIDASE; ANTINEOPLASTIC AGENT; ARYLSULFATASE; BETA GLUCOSIDASE; BETA GLUCURONIDASE; BETA LACTAMASE; CAMPTOTHECIN; CARBOXYPEPTIDASE A; CARBOXYPEPTIDASE G2; CHLORAMPHENICOL DERIVATIVE; CYTOSINE DEAMINASE; DOXORUBICIN; ENZYME; ETOPOSIDE; FLUOROURACIL; FOLIC ACID ANTAGONIST; GLUCOSE OXIDASE; HYBRID PROTEIN; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; NITROREDUCTASE; PENICILLIN AMIDASE; PRODRUG; UNINDEXED DRUG; XANTHINE OXIDASE;

CANCER REGRESSION; CANCER TISSUE; CLINICAL TRIAL; COLORECTAL CANCER; CONJUGATE; DRUG ACTIVATION; DRUG ACTIVITY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG TARGETING; DRUG TISSUE LEVEL; ENZYME ACTIVITY; HUMAN; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; ENZYMES; HUMANS; PRODRUGS;

EID: 0035980983     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(01)00206-X     Document Type: Review

References (103)

1. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs
2. The design of selectively-activated prodrugs for cancer chemotherapy
3. Prodrugs of anticancer agents
4. Targeted delivery of chemotherapeutics: Tumor-activated prodrug therapy
5. Recombinant antibody fragments and immunotoxin fusions for cancer therapy
6. The emerging role of radioimmunotherapy in haematological malignancies
7. Targeted therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates
8. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxentan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
9. Monoclonal antibody therapy in lymphoid malignancies
10. Herceptin (trastuzamab) in advanced breast cancer
11. Antibodies in the therapy of colon cancer
12. Delivery of molecular and cellular medicine to solid tumors
13. Antibody-directed enzyme prodrug therapy (ADEPT): A review
14. Antibody directed enzyme prodrug therapy (ADEPT): A review of the experimental and clinical considerations
15. Antibody-directed enzyme-prodrug therapy (ADEPT)
16. Activation of prodrugs by antibody-enzyme conjugates: A new approach to cancer therapy
17. Novel anthracycline-spacer-β-glucuronide, β-glucoside, and β-galactoside prodrugs for application in selective chemotherapy
18. Characterization of novel anthracycline prodrugs activated by human β-glucuronidase for use in antibody-directed enzyme prodrug therapy
19. Design and synthesis of novel pyrrolobenzodiazepine (PBD) prodrugs for ADEPT and GDEPT
20. A 2-nitroimidazole carbamate prodrug of 5-amino-1-(chloromethyl)-3-[5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2- dihydro-3H-benz[E]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT
21. Synthesis and evaluation of 4-substituted analogues of 5-[N,N-bis (2-chloroethyl)amino]-2-nitrobenzamide as bioreductively activated prodrugs using an Escherichia coli nitroreductase
22. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase
23. Self-immolative prodrugs: Candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme
24. Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT)
25. Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate
26. Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates
27. In vitro and in vivo activities of monoclonal antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate
28. Methotrexate-α-phenylalanine: Optimization of methotrexate prodrug for activation by carboxypeptidase A-monoclonal antibody conjugate
29. Activation of methotrexate-α-phenylalanine by monoclonal antibody-carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro
30. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate
31. Prodrugs of thymidylate synthase inhibitors: Potential for antibody directed enzyme prodrug therapy (ADEPT)
32. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: In vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843
33. Tumor-selective prodrug activation by fusion protein-mediated catalysis
34. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy
35. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard
36. Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug
37. Direct in vivo observation of 5-fluorouracil release from a prodrug in human tumors heterotransplanted in nude mice: A magnetic resonance study
38. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT)
39. Application of the strategy to the MDR resistance in cancer chemotherapy
40. Selective cytotoxicity of hapten-substituted cells with an antibody-enzyme conjugate
41. A cytotoxic agent can be generated selectively at cancer sites
42. Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugate
43. Application of monoclonal antibodies against cytosine deaminase for the in vivo clearance of a cytosine deaminase immunoconjugate
44. Intratumoral generation of 5-flourouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine
45. Intratumoral conversion of 5-fluorocytosine to 5-fluorouracil by monoclonal antibody-cytosine deaminase conjugates: Noninvasive detection of prodrug activation by magnetic resonance spectroscopic imaging
46. Cephalosporin nitrogen mustard carbamate prodrugs for 'ADEPT'
47. A N-nitrosochloroethyl-cephalosporine carbamate prodrug for antibody-directed enzyme prodrug therapy (ADEPT)
48. Development and activities of a new melphalan prodrug designed for tumor-selective activation
49. Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-β-lactamase conjugates
50. Cephalosporin derivatives of doxorubicin as prodrugs for activation by monoclonal antibody-β-lactamase conjugates
51. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug
52. Site-specific prodrug activation by antibody-β-lactamase conjugates: Preclinical investigation of the efficacy and toxicity of doxorubicin delivered by antibody directed catalysis
53. Immunologically specific cephalosporin derivative of mitomycin C by monoclonal antibody β-lactamase conjugates
54. Site-specific prodrug activation by antibody-β-lactamase conjugates: Regressions and long-term growth inhibition of human colon carcinoma xenograft models
55. Synthesis and β-lactamase-mediated activation of cephalosporin-taxol prodrug
56. Design and synthesis of a cephalosporin-carboplatinum prodrug activatable by a β-lactamase
57. A new cephalosporin with a dual mode of action
58. Conscripting β-lactamase for use in drug delivery. Synthesis and biological activity of a cephalosporin C 10-ester of an antibiotic dipeptide
59. Regressions and cures of melanoma xenografts following treatment with monoclonal antibody β-lactamase conjugates in combination with anticancer prodrugs
60. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody β-lactamase conjugates
61. High yield, site-specific coupling of N-terminally modified β-lactamase to a proteolytically derived single-sulfhydryl murine Fab
62. Genetic construction, expression and characterization of a single chain anti-carcinoma antibody fused to β-lactamase
63. Construction, expression, and activities of L49-sFv-β-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation
64. Comparison of recombinant and synthetically formed monoclonal antibody-β-lactamase conjugate for anticancer prodrug activation
65. Accelerated clearance systems
66. Synthesis of an N-mustard prodrug
67. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2
68. CMDA, an antineoplastic prodrug
69. Comparison of half-lives and cytotoxicity of N-mesyloxyethyl-and N-chloroethyl-4-amino benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT)
70. Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds
71. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against C-erbB2p185
72. Antibody-directed prodrug therapy (ADEPT): A three-phase study in ovarian tumour xenografts
73. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent
74. Disposition of the prodrug 4-[bis(2-chloroethyl)amino]benzoyl-L-glutamic acid and its active parent drug in mice
75. Endogenous activation of a prodrug in antibody directed enzyme prodrug therapy
76. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs
77. Anti-tumour effects on an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs
78. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: A new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT)
79. Antibody directed enzyme prodrug therapy: A pilot-scale clinical trial
80. First clinical experience with ADEPT
81. Antibody-directed enzyme prodrug therapy: Efficacy and mechanism of action in colorectal carcinoma
82. Catalytic activity of an in vivo tumor targeted anti-CEA-scFv-carboxypeptidase G2 fusion protein
83. Molecular and functional characterization of a fusion protein suited for tumour specific prodrug activation
84. Elucidation of the mechanism enabling tumor selective prodrug monotherapy
85. Prodrug activation via catalytic antibodies
86. Antibody-catalyzed prodrug activation
87. Toward antibody-directed 'abzyme' prodrug therapy, ADAPT: Carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing
88. Multiple event activation of a generic prodrug trigger by antibody catalysis
89. Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: Comparison with experimental data
90. Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: Comparison with experimental data
91. Mathematical and experimental analysis of localization of anti-tumour antibody-enzyme conjugates
92. Development and validation of a mathematical model to describe anti-cancer prodrug activation by antibody-enzyme conjugates
93. Synthesis of α-aminoacyl derivatives of melphalan for use in antibody directed enzyme prodrug therapy
94. Sulfated etoposide and nitrogen mustard prodrugs and their activation by streptomyces arylsulfatase
95. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts
96. Prodrugs of anthracycline antibiotics suited for tumor-specific activation
97. Conjugates of COL-1 monoclonal antibody and beta-D-galactosidase can specifically kill tumor cells by generation of 5-fluorouridine from the prodrug beta-D-galactosyl-5-fluorouridine
98. Intensely cytotoxic anthracycline prodrugs: Galactosides
99. Prodrugs of anthracyclines for chemotherapy via enzyme-monoclonal antibody conjugates
100. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms
101. Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate
102. N-(4′-Hydroxphenylacetyl)palytoxin: A palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate
103. Tumor-targeting chemotherapy by a xanthine oxidase-polymer conjugate that generates oxygen-free radicals in tumor tissue